<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36301542</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Prevalence and Correlates of Long COVID Symptoms Among US Adults.</ArticleTitle><Pagination><StartPage>e2238804</StartPage><MedlinePgn>e2238804</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2238804</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2022.38804</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Persistence of COVID-19 symptoms beyond 2 months, or long COVID, is increasingly recognized as a common sequela of acute infection.</AbstractText><AbstractText Label="OBJECTIVES">To estimate the prevalence of and sociodemographic factors associated with long COVID and to identify whether the predominant variant at the time of infection and prior vaccination status are associated with differential risk.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study comprised 8 waves of a nonprobability internet survey conducted between February 5, 2021, and July 6, 2022, among individuals aged 18 years or older, inclusive of all 50 states and the District of Columbia.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Long COVID, defined as reporting continued COVID-19 symptoms beyond 2 months after the initial month of symptoms, among individuals with self-reported positive results of a polymerase chain reaction test or antigen test.</AbstractText><AbstractText Label="RESULTS">The 16&#x202f;091 survey respondents reporting test-confirmed COVID-19 illness at least 2 months prior had a mean age of 40.5 (15.2) years; 10&#x202f;075 (62.6%) were women, and 6016 (37.4%) were men; 817 (5.1%) were Asian, 1826 (11.3%) were Black, 1546 (9.6%) were Hispanic, and 11&#x202f;425 (71.0%) were White. From this cohort, 2359 individuals (14.7%) reported continued COVID-19 symptoms more than 2 months after acute illness. Reweighted to reflect national sociodemographic distributions, these individuals represented 13.9% of those who had tested positive for COVID-19, or 1.7% of US adults. In logistic regression models, older age per decade above 40 years (adjusted odds ratio [OR], 1.15; 95% CI, 1.12-1.19) and female gender (adjusted OR, 1.91; 95% CI, 1.73-2.13) were associated with greater risk of persistence of long COVID; individuals with a graduate education vs high school or less (adjusted OR, 0.67; 95% CI, 0.56-0.79) and urban vs rural residence (adjusted OR, 0.74; 95% CI, 0.64-0.86) were less likely to report persistence of long COVID. Compared with ancestral COVID-19, infection during periods when the Epsilon variant (OR, 0.81; 95% CI, 0.69-0.95) or the Omicron variant (OR, 0.77; 95% CI, 0.64-0.92) predominated in the US was associated with diminished likelihood of long COVID. Completion of the primary vaccine series prior to acute illness was associated with diminished risk for long COVID (OR, 0.72; 95% CI, 0.60-0.86).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study suggests that long COVID is prevalent and associated with female gender and older age, while risk may be diminished by completion of primary vaccination series prior to infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santillana</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ognyanova</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Communication, School of Communication and Information, Rutgers University, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safarpour</LastName><ForeName>Alauna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>John F. Kennedy School of Government and Department of Government, Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunz Trujillo</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>John F. Kennedy School of Government and Department of Government, Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonson</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Political Science, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>Alexi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druckman</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northwestern University, Evanston, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baum</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John F. Kennedy School of Government and Department of Government, Harvard University, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Political Science, Northeastern University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Perlis reported receiving personal fees from Burrage Capital, Genomind, Psy Therapeutics, Takeda, and Circular Genomics outside the submitted work. Dr Lazer reported receiving grants from the National Science Foundation during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36301542</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pii">2797782</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patient-Led Research Collaborative . Report: what does COVID-19 recovery actually look like? Accessed April 30, 2022. https://patientresearchcovid19.com/research/report-1/</Citation></Reference><Reference><Citation>National Institute for Health and Care Exellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. Published December 18, 2020. Last updated November 11, 2021. Accessed April 30, 2022. https://www.nice.org.uk/guidance/ng188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Accessed June 21, 2022. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. Accessed April 30, 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021</Citation></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18-64 and &#x2265;65 years&#x2014;United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713-717. doi:10.15585/mmwr.mm7121e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro VM, Rosand J, Giacino JT, McCoy TH, Perlis RH. Case-control study of neuropsychiatric symptoms in electronic health records following COVID-19 hospitalization in 2 academic health systems. Mol Psychiatry. 2022. doi:10.1038/s41380-022-01646-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01646-z</ArticleId><ArticleId IdType="pmc">PMC9199464</ArticleId><ArticleId IdType="pubmed">35705635</ArticleId></ArticleIdList></Reference><Reference><Citation>Honigsbaum M, Krishnan L. Taking pandemic sequelae seriously: from the Russian influenza to COVID-19 long-haulers. Lancet. 2020;396(10260):1389-1391. doi:10.1016/S0140-6736(20)32134-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32134-6</ArticleId><ArticleId IdType="pmc">PMC7550169</ArticleId><ArticleId IdType="pubmed">33058777</ArticleId></ArticleIdList></Reference><Reference><Citation>Azar KMJ, Shen Z, Romanelli RJ, et al. . Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. Health Aff (Millwood). 2020;39(7):1253-1262. doi:10.1377/hlthaff.2020.00598</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2020.00598</ArticleId><ArticleId IdType="pubmed">32437224</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeting the challenge of long COVID. Nature Medicine. Accessed April 8, 2022. https://www.nature.com/articles/s41591-020-01177-6</Citation><ArticleIdList><ArticleId IdType="pubmed">33288947</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. Preprint posted online December 19, 2020. doi:10.1101/2020.10.19.20214494</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.19.20214494</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55. doi:10.1016/S1473-3099(21)00460-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy C, Caumont R. What we learned about online nonprobability polls. Pew Research Center. Published May 2, 2016. Accessed April 7, 2022. https://www.pewresearch.org/fact-tank/2016/05/02/q-a-online-nonprobability-polls/</Citation></Reference><Reference><Citation>Coppock A, McClellan OA. Validating the demographic, political, psychological, and experimental results obtained from a new source of online survey respondents. Res Polit. 2019;6(1):2053168018822174. doi:10.1177/2053168018822174</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2053168018822174</ArticleId></ArticleIdList></Reference><Reference><Citation>Berinsky AJ, Huber GA, Lenz GS. Evaluating online labor markets for experimental research: Amazon.com&#x2019;s Mechanical Turk. Political Analysis. 2012;20(3):351-368. doi:10.1093/pan/mpr057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pan/mpr057</ArticleId></ArticleIdList></Reference><Reference><Citation>American Association for Public Opinion Research . Survey disclosure checklist. 2021. Accessed January 25, 2022. https://www.aapor.org/Standards-Ethics/AAPOR-Code-of-Ethics/Survey-Disclosure-Checklist.aspx</Citation></Reference><Reference><Citation>Flanagin A, Frey T, Christiansen SL; AMA Manual of Style Committee . Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326(7):621-627. doi:10.1001/jama.2021.13304</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.13304</ArticleId><ArticleId IdType="pubmed">34402850</ArticleId></ArticleIdList></Reference><Reference><Citation>CoVariants . CoVariants: SARS-CoV-2 mutations and variants of interest. Accessed July 4, 2022. https://covariants.org/</Citation></Reference><Reference><Citation>R Core Team . R: a language and environment for statistical computing. 2019. Accessed July 4, 2022. http://www.R-project.org</Citation></Reference><Reference><Citation>United States Census Bureau . American Community Survey (ACS). Accessed April 28, 2022. https://www.census.gov/programs-surveys/acs</Citation></Reference><Reference><Citation>Czeisler M&#xc9;, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic&#x2014;United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057. doi:10.15585/mmwr.mm6932a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6932a1</ArticleId><ArticleId IdType="pmc">PMC7440121</ArticleId><ArticleId IdType="pubmed">32790653</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Simonson MD, Green J, et al. . Prevalence of firearm ownership among individuals with major depressive symptoms. JAMA Netw Open. 2022;5(3):e223245. doi:10.1001/jamanetworkopen.2022.3245</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.3245</ArticleId><ArticleId IdType="pmc">PMC8938748</ArticleId><ArticleId IdType="pubmed">35311961</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford J, Green J, Quintana A, et al. . Evaluating the generalizability of the COVID States survey&#x2014;a large-scale, non-probability survey. OSF Preprints. Preprint posted online March 7, 2022. doi:10.31219/osf.io/cwkg7</Citation><ArticleIdList><ArticleId IdType="doi">10.31219/osf.io/cwkg7</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVER . RECOVER: Researching COVID to Enhance Recovery. Accessed June 20, 2022. https://recovercovid.org</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>